La sclérose tubéreuse de Bourneville (STB) est une maladie génétique et multi-systémique à transmission autosomique dominante due à des mutations d’un gène TSC1 ou TSC2 qui codent respectivement pour hamartine et tuberine ayant une action inhibitrice sur la voie de signalisation mTOR. L’épilepsie précoce et pharmacorésistante est la manifestation neurologique la plus fréquente et la plus délétère de la STB. Elle débute souvent dans la première année de vie par des spasmes infantiles qui évoluent avec l’âge et en absence de traitement vers des crises toniques ou tonico-cloniques. Bien que les crises soient supposées être générées dans des tubers corticaux, les mécanismes de l’épilepsie ne sont pas bien élucidés et le traitement reste souvent inefficace. Des études morphologiques ont montré une altération de l’expression ARNm des récepteurs au glutamate dans les cellules géantes et les neurones dysplasiques des tubers, mais leur implication fonctionnelle restait à montrer. Les différentes sous-unités NMDA ont une expression âge-dépendante et région-spécifique, les plus grands changements survenant au début de la vie quand l’épilepsie de la STB apparaît. Ce travail avait pour but d’étudier à l’aide de méthodes électrophysiologiques in vitro et in vivo l’expression fonctionnelle des sous-unités NMDA aberrantes et de déterminer leur rôle dans l’épileptogènese chez les souris hétérozygotes Tsc1+/- et sur le tissu humain STB post-opératoire. Nous avons pu démontrer que : i) Les souris hétérozygotes pour le gène Tsc1 sont spontanément épileptiques in vivo et in vitro dans une courte fenêtre dévelopmentale de P9 à P18. ii) Elles présentent une altération d’expression des récepteurs NMDA couche-spécifique et mTOR dépendante avec une surexpression des sous-unités GluN2C/D dans la couche 4 et 2/3 et GluN2B dans les couches 2/3. Cette expression anormale est prévenue par l’administration d’un inhibiteur de la voie mTOR, la rapamycine. iii) Les mêmes altérations d’expression des récepteurs NMDA, sont montrées sur les tissus post-opératoires, non seulement de tubers de STB mais aussi des dysplasies corticales focales (DCF), ces deux malformations ayant des similarités étiologiques et physiopathologiques. iv) La RT-PCR quantitative confirme une expression excessive de GluN2C dans le cortex de souris Tsc1+/- et sur le tissu humain des tubers et DCF. v) Les décharges épileptiques chez la souris Tsc1+/- sont générées dans la couche granulaire 4 du cortex avant de se propager vers les couches superficielles et les couches profondes, empruntant ainsi les microcircuits corticaux. vi) L’expression excessive de la sous-unité GluN2C dans le cortex contribue à l’hyperexcitabilité neuronale chez la souris Tsc1+/- et sur des tissus humains de tubers et de DCF puisque les crises et les décharges sont bloquées par les antagonistes sélectifs de GluN2C/D. vii) Les crises chez la souris Tsc1+/- suivent une séquence âge-dépendante évoluant du type «spasms-like» vers «tonic-clonic like», rappelant celle de l’épilepsie humaine, avec deux pics de haute incidence de crises à P13 et P16 correspondant chez l’homme respectivement l’âge des spasmes infantiles et celui des crises toniques. L’évolution avec l’âge du délai de propagation inter-hémisphérique pourrait contribuer à ce changement de types de crises. Ces résultats montrent donc pour la première fois qu’une happloinsuffisance pour le gène Tsc1 chez les souris Tsc1+/- sans tubers suffit à produire une altération de l’expression des récepteurs NMDA de manière mTOR dépendante et contribuer ainsi à l’épileptogènese dans la STB. La souris Tsc1+/- est le premier modèle génétique sans anomalies morphologiques présentant une épilepsie spontanée qui évolue des spasmes vers des crises toniques et tonico-cloniques. Néanmoins cette épilepsie diffère de l’épilepsie humaine de la STB par l’absence de crises focales et de pharmacorésistance, ce qui pourrait être expliqué par l’absence de tubers chez la souris Tsc1+/-. (...) / Tuberous sclerosis complex (TSC) is a genetic multisystemic disease with autosomal dominant transmission due to mutations in a gene TSC1 or TSC2 respectively which encode hamartin and tuberin proteins having an inhibitory action on the mTOR signaling pathway. Early refractory epilepsy is the most common and most deleterious neurological manifestation. The epilepsy often begins in the first year of life by infantile spasms that change in the lack of treatment to tonic or tonic-clonic seizures in age-dependent manner. Although seizures are thought to be generated in cortical tubers, epilepsy mechanisms are not well understood and treatment is often ineffective. Morphological studies showed the altered expression of glutamate receptor mRNA in the giant cells and dysplastic neurons of tubers, but their functional involvement remains unknown. The different NMDA subunits have an age-dependent and region-specific expression, the greatest changes occurring early in life when the TSC epilepsy appears. This work aimed to study the functional expression of aberrant NMDA subunits expression and their role in the epileptogenesis in heterozygous Tsc1+/- mice and post-surgical human tissue of TSC patients using in vitro and in vivo electrophysiological methods. The study reveal that: i) Heterozygous tuber-free Tsc1+/- mice show spontaneous epilepsy in vivo and in vitro in a short developmental window from P9 to P18. ii) These mice exhibit an altered NMDA receptor expression in mTOR dependent and layer-specific manner with GluN2C/D subunits overexpression in layers 4 and 2/3, and GluN2B ovexpression in layers 2/3. This abnormal NMDA receptors expression is prevented by the administration of an mTOR inhibitor, rapamycin. iii) The same alterations of NMDA receptors’ expression are shown in post-surgical tissues not only in tubers from TSC patients, but also in focal cortical dysplasia (FCD), these two malformations sharing etiological and pathophysiological similarities. iv) Quantitative RT-PCR confirms the excessive GluN2C subunit expression in Tsc1+/- mouse cortex and human tissue of tubers and DCF. v) Epileptic discharges in Tsc1+/- mice are generated in the granular layer 4 of the cortex before spreading to the superficial and then to deep layers, thus borrowing the cortical microcircuits. vi) Excessive expression of GluN2C subunit in the cortex contributes to neuronal hyperexcitability in Tsc1+/- mice, as well as in human tubers and DCF tissues, since epileptic discharges are blocked by selective GluN2C/D antagonists. vii) Seizures in Tsc1+/- mice follow the age-dependent sequence, evolving from "spasms-like" to "tonic-clonic like" thus reminding the human epilepsy, with two peaks of highest seizure incidence at P13 and P16 corresponding respectively to age of infantile spasms and of tonic seizures in human. The age-dependent evolution of interhemispheric propagation delay could contribute to this change in seizure type. These results show for the first time that TSC1 happloinsuffisancy in tuber-free Tsc1+/- mice is sufficient to produce an alteration in NMDA receptor expression in an mTOR dependent manner, and thus contributes to epileptogenesis in TSC. The Tsc1+/- mouse line is the first genetic model of TSC without morphological abnormalities presenting with early spontaneous seizures which evolves from “spasms-like” to “tonic-clonic like” seizures. However, the epilepsy in Tsc1+/- mice differs from human TSC epilepsy by the absence of focal seizures and of drug-resistance. Both could be explained by the lack of tubers in the Tsc1+/- mice. It remains to determine whether the expression of GluN2C subunit is also transitional in Tsc1+/- mice and whether other factors contribute to determine the age-dependent epilepsy. This study opens new therapeutic perspectives of TSC epilepsy targeting GluN2C subunit of NMDA receptors.

La voie dopaminergique mésolimbique qui prend son origine dans le mésencéphale ventral et qui projette vers des régions rostrales du système limbique fait partie du substrat nerveux qui contrôle la récompense et les comportements motivés. Il a été suggéré qu’un signal de récompense est produit lorsque le patron de décharge des neurones dopaminergiques passe d’un mode tonique à un mode phasique, une transition qui est initiée par l’action du glutamate aux récepteurs N-Méthyl-D-aspartate (NMDA). Étant donné qu’une altération du système de récompense est souvent associée à des anomalies cliniques telles que l’addiction compulsive et à des troubles émotionnels tels que l’anhédonie, nous avons étudié le rôle des récepteurs NMDA dans la récompense induite par la stimulation électrique intracérébrale. Puisque les récepteurs NMDA sont composés de sous-unités distinctes, GluN1, GluN2 et GluN3, nous avons étudié le rôle de deux sous-unités qui sont présentes dans le mésencéphale ventral : GluN2A et GluN2B. Les résultats montrent que des injections mésencéphaliques de R-CPP et de PPPA, des antagonistes préférentiels aux sous-unités GluN2A/B, ont produit une augmentation dose-dépendante de l’effet de récompense, un effet qui était, à certains temps après les injections, accompagné d’une augmentation du nombre de réponses maximales. Ces effets n’ont pas été observés après l’injection d’une large gamme de doses de Ro04-5595, un antagoniste des sous-unités GluN2B. Ces résultats suggèrent que le glutamate mésencéphalique exerce une modulation négative sur le circuit de récompense, un effet dû à son action au niveau des récepteurs NMDA composés des sous-unités GluN2A. / The mesolimbic dopaminergic pathway, originating from the ventral midbrain and projecting to rostral limbic structures, is part of a neural substrate that controls reward and incentive behaviors. It has been suggested that the rewarding effect is produced by a tonic to phasic shift in dopamine cell firing and a transduction process initiated by the action of glutamate at the N-Methyl-D-aspartate (NMDA) receptors. Given that an alteration in reward signaling is often associated with clinical symptoms of compulsive addictive behaviors and emotional disturbances such as anhedonia, we investigated the role of NMDA receptors in reward induced by intracranial electrical stimulation. Since NMDA receptors are composed of distinct subunits, GluN1, GluN2 and GluN3, we investigated the role of the main GluN2 subunits that are expressed in the ventral midbrain, GluN2A and GluN2B. Results show that ventral midbrain injections of R-CPP or PPPA, preferential GluN2A/2B antagonists, produce a dose-orderly enhancement of reward, an effect that was, at some time after the injection, accompanied by an increase in maximum response rates. These effects were not observed following ventral midbrain injections of a wide range of doses of the selective GluN2B antagonist, Ro-04-5595. These findings suggest that ventral midbrain glutamate exerts a negative modulation on reward induced by electrical stimulation of the posterior mesencephalon, an effect most likely mediated by NMDA receptors composed of GluN2A subunits.

Le fonctionnement du cortex cérébral nécessite l’action coordonnée de deux des sous-types majeurs de neurones, soient les neurones à projections glutamatergiques et les interneurones GABAergiques. Les interneurones GABAergiques ne constituent que 20 à 30% des cellules corticales par rapport au grand nombre de neurones glutamatergiques. Leur rôle est toutefois prépondérant puisqu’ils modulent fortement la dynamique et la plasticité des réseaux néocorticaux. Il n’est donc pas surprenant que les altérations de développement des circuits GABAergiques soient associées à plusieurs maladies du cerveau, incluant l’épilepsie, le syndrome de Rett et la schizophrénie. La compréhension des mécanismes moléculaires régissant le développement des circuits GABAergiques est une étape essentielle menant vers une meilleure compréhension de la façon dont les anormalités se produisent. Conséquemment, nous nous intéressons au rôle de l’acide polysialique (PSA) dans le développement des synapses GABAergiques. PSA est un homopolymère de chaînons polysialylés en α-2,8, et est exclusivement lié à la molécule d’adhésion aux cellules neuronales (NCAM) dans les cerveaux de mammifères. PSA est impliqué dans plusieurs processus développementaux, y compris la formation et la plasticité des synapses glutamatergiques, mais son rôle dans les réseaux GABAergiques reste à préciser. Les données générées dans le laboratoire du Dr. Di Cristo démontrent que PSA est fortement exprimé post- natalement dans le néocortex des rongeurs, que son abondance diminue au cours du développement, et, faits importants, que son expression dépend de l’activité visuelle i et est inversement corrélée à la maturation des synapses GABAergiques. La présente propose de caractériser les mécanismes moléculaires régulant l’expression de PSA dans le néocortex visuel de la souris. Les enzymes polysialyltransférases ST8SiaII (STX) et ST8SiaIV (PST) sont responsables de la formation de la chaîne de PSA sur NCAM. En contrôlant ainsi la quantité de PSA sur NCAM, ils influenceraient le développement des synapses GABAergiques. Mon projet consiste à déterminer comment l’expression des polysialyltransférases est régulée dans le néocortex visuel des souris durant la période post-natale; ces données sont à la fois inconnues, et cruciales. Nous utilisons un système de cultures organotypiques dont la maturation des synapses GABAergiques est comparable au modèle in vivo. L’analyse de l’expression génique par qPCR a démontré que l’expression des polysialyltransférases diminue au cours du développement; une baisse majeure corrélant avec l’ouverture des yeux chez la souris. Nous avons de plus illustré pour la première fois que l’expression de STX, et non celle de PST, est activité-dépendante, et que ce processus requiert l’activation du récepteur NMDA, une augmentation du niveau de calcium intracellulaire et la protéine kinase C (PKC). Ces données démontrent que STX est l’enzyme régulant préférentiellement le niveau de PSA sur NCAM au cours de la période post-natale dans le cortex visuel des souris. Des données préliminaires d’un second volet de notre investigation suggèrent que l’acétylation des histones et la méthylation de l’ADN pourraient également contribuer à la régulation de la transcription de cette enzyme durant le développement. Plus d’investigations seront toutefois nécessaires afin de confirmer cette hypothèse. En somme, la connaissance des mécanismes par lesquels l’expression des ii polysialyltransférases est modulée est essentielle à la compréhension du processus de maturation des synapses GABAergiques. Ceci permettrait de moduler pharmacologiquement l’expression de ces enzymes; la sur-expression de STX et/ou PST pourrait produire une plus grande quantité de PSA, déstabiliser les synapses GABAergiques, et conséquemment, ré-induire la plasticité cérébrale. / The functioning of the cerebral cortex requires coordinated action of two major neuronal subtypes - the glutamatergic projection neurons and the GABAergic interneurons. GABAergic interneurons represent 20 to 30% of all cortical cells. Even though they are a minor cell population in the cerebral cortex compared to glutamatergic neurons, they are key modulators of network dynamics and plasticity of neocortical circuits. It is therefore not surprising that aberrant development of GABAergic circuits is implicated in many neurodevelopmental disorders including epilepsy, Rett syndrome and schizophrenia. Understanding the molecular mechanisms governing the development of GABAergic inhibitory synapses in neocortex is important towards a better comprehension of how abnormalities in this developmental process can occur. Therefore, we focus specifically on the role of polysialic acid (PSA) in the development of GABAergic synapses. PSA is a α-2,8 polysialylated homopolymer, which is exclusively linked to the Neural Cell Adhesion Molecule (NCAM) in the mammalian brain. It is involved in several developmental processes including formation and plasticity of glutamatergic synapses; however its role in GABAergic circuit formation has not been explored so far. Previously in Dr Di Cristo’s lab, we showed that PSA is strongly expressed post-natally and its expression steadily declines during development in mice neocortex. We also showed that the developmental and activity-dependant regulation of PSA expression is inversely correlated with the maturation of perisomatic GABAergic innervation. Our aim is to characterize the molecular mechanisms regulating PSA expression in mouse iv visual cortex during post-natal development. Two polysialyltransferases, ST8SiaII (STX) and ST8SiaIV (PST), are responsible for PSA attachment to NCAM. By controlling the amount of PSA on NCAM, they can influence GABAergic synapses development. The mechanisms regulating STX and PST expression is crucial but remain still unknown. My research project focused on the mechanisms regulating STX and PST transcription in the mouse postnatal cortex. We used an organotypic culture system, which recapitulates many aspects of GABAergic synapse maturation as observed in vivo. Polysialyltransferases transcript levels were measured by qPCR and showed that STX and PST mRNA levels steadily decline during post-natal development in the mouse cortex; the sharpest reduction in the expression of both enzymes correlate with eye opening. We further demonstrate for the first time that STX mRNA levels is activity-dependant, requires the activation of NMDA receptors, an increase in intracellular Calcium levels and is PKC-dependent. Altogether, we show that the regulation of the expression of STX is the main mechanism responsible for PSA expression levels in the cortex around eyes opening. We next investigated whether epigenetic mechanisms regulate STX transcription and preliminary data suggest that histone acetylation and DNA methylation may contribute to STX expression during development. However, further experiments are required to confirm this hypothesis. In summary, understanding the mechanisms modulating STX and PST expression in the neocortex is essential for the comprehension of their precise role in GABAergic synapse maturation. This knowledge could allow us to modulate pharmacologically the expression of these enzymes; in turn overexpression of STX and PST may re-induce PSA expression, thereby destabilizing GABAergic synapses, and ultimately facilitating cortical plasticity in the adult.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Spermidine (SPD) is an endogenous polyamine with polycationic structure present in the central nervous system of mammals. SPD regulates biological processes, such as Ca2+ influx by glutamatergic N-methyl-D-aspartate receptor (NMDA receptor), which has been associated with nitric oxide synthase (NOS) and cGMP/PKG pathway activation and a decrease of Na+,K+-ATPase activity in rats cerebral córtex synaptossomes. Decreased Na+,K+-ATPase activity, as well as decreased enzyme expression, directly impairs neurotransmitter signaling with deleterious consequences on learning and memory. The enzyme Na+,K+-ATPase establishes Na+ and K+ gradients across membranes of excitable cells and by this means maintains membrane potential and controls intracellular pH and volume. However, it has not been defined whether SPD modulates Na+,K+-ATPase activity in the hippocampus. In this study we investigated whether SPD alters Na+,K+-ATPase activity in slices of hippocampus from rats, and possible underlying mechanisms. Hippocampal slices and homogenates were incubated with SPD (0.05-10 μM) for 30 minutes. SPD (0.5 and 1 μM) decreased Na+,K+-ATPase activity in slices, but not in homogenates. MK-801 (100 μM), a non-competitive antagonist of NMDA receptor, arcaine (0.5 μM), an antagonist of the polyamine binding site at the NMDA receptor, and L-NAME (100 μM), a nitric oxide synthase inhibitor, prevented the inhibitory effect of SPD (0.5 μM). ODQ (10 μM), a guanylate cyclase inhibitor, and KT5823 (2 μM), a protein kinase G inhibitor, also prevented the inhibitory effect of SPD on Na+,K+-ATPase activity. SPD (0.5 and 1.0 μM) increased NO2 plus NO3 (NOx) levels in slices, MK-801 (100 μM) and arcaine (0.5 μM) prevented the effect of SPD (0.5 μM) on the NOx content. These results suggest that SPD-induced decrease of Na+,K+-ATPase activity involves NMDA/NOS/cGMP/PKG pathway. / A espermidina (SPD) é uma poliamina endógena com estrutura policatiônica presente no sistema nervoso central (SNC) de mamíferos. A SPD regula muitos processos biológicos, como o influxo de cálcio através dos receptores glutamatérgicos N-metil-D-aspartato (NMDA), o qual tem sido associado com a ativação da enzima óxido nítrico sintase (NOS) e da via de sinalização da guanosina mono fosfato cíclica/proteína quinase dependente de GMPc (GMPc/PKG). Sabe-se que uma diminuição da atividade da Na+,K+-ATPase, bem como a sua expressão, prejudica diretamente a sinalização de neurotransmissores, comprometendo tanto aprendizado e a memória. A enzima Na+,K+-ATPase estabelece os gradientes de Na+ e K+ através da membrana de células excitáveis e desta forma mantém o potencial de membrana e contribui para o controle do volume e do pH celular. No entanto, não está bem definido se a SPD modula a atividade da Na+,K+-ATPase no hipocampo de ratos. Neste estudo foi investigado se SPD altera a atividade da Na+,K+-ATPase em fatias de hipocampo de ratos, e o possível mecanismo envolvido neste processo. As fatias e o homogeneizado de hipocampo foram incubados com SPD (0,05-10 M) por 30 minutos. SPD (0,5 e 1 M) diminuíram a atividade da Na+,K+-ATPase em fatias, mas não no homogeneizado de hipocampo. MK-801 (100 μM), um antagonista não competitivo do receptor NMDA, arcaína (0,5 M), um antagonista do sítio de ligação das poliaminas no receptor NMDA, e L-NAME (100 μM), um inibidor da NOS, preveniram o efeito inibitório da SPD (0,5 M). ODQ (10 μM), um inibidor da enzima guanilato ciclase, e KT5823 (2 μM), um inibidor da proteína quinase dependente de GMPc, também preveniram o efeito inibitório da SPD sobre a atividade da Na+,K+-ATPase. SPD (0,5 e 1,0 μM) aumentaram os níveis de NO2 plus NO3 (NOx) nas fatias de hipocampo. MK-801 (100 μM) e arcaína (0,5 μM) preveniram o efeito da SPD (0,5 μM) sobre conteúdo de NOx. Estes resultados sugerem que a diminuição da atividade da Na+,K+-ATPase induzida pela SPD envolve a via de sinalização NMDA/NOS/GMPc/PKG.

No description available.

L’objectif de ce travail a été de tester l’hypothèse selon laquelle l’effet bénéfique de l’administration de la forme recombinante de l’activateur tissulaire du plasminogène (rt-PA) chez le patient victime d’un accident vasculaire cérébral (AVC) ischémique ne résulte pas uniquement de son action fibrinolytique mais aussi de sa capacité à augmenter le brain-derived neurotrophic factor (BDNF) dans le cerveau. Dans ce but, nous avons conduit une première étude visant à évaluer chez l’animal sain, l’effet du rt-PA sur les taux cérébraux de BDNF. Dans une seconde approche, nous avons étudié l’effet du rt-PA sur les taux sériques de BDNF chez le patient victime d’un AVC ischémique et chez l’animal soumis à une ischémie cérébrale focale. Le sang a été prélevé chez l’Homme à l’admission (J0), J1, J7 et J90 après l’AVC, et chez le Rat avant et après (1h, 4h et 24h) l’ischémie. Le BDNF a été mesuré dans le cerveau par technique de Western blot et dans le sang par technique ELISA. Dans les deux études le rt-PA (Actilyse®) a été administré sous forme d’un bolus suivi d’une perfusion d’une heure. La première étude montre que 1) le rt-PA augmente les taux de BDNF dans l’hippocampe, 2) le traitement par MK801 (un antagoniste des récepteurs NMDA) mais pas par l’acide tranexamique (un inhibiteur de la plasmine) annule l’effet du rt-PA sur les taux de BDNF. La deuxième étude met en évidence que 1) la récupération neurologique est meilleure chez les patients recevant le rt-PA, 2) le traitement par rt-PA augmente les taux sériques de BDNF à J1 et J7 chez l’Homme, mais ne modifie pas les taux sanguins de BDNF chez l’animal, 3) les taux de BDNF ne sont pas corrélés à la récupération neurologique mais sont inversement corrélés au score cardiovasculaire du patient. En conclusion, nos résultats suggèrent que le rt-PA peut exercer un effet protecteur extra-fibrinolytique en augmentant les taux de BDNFm par une potentialisation de l’activité glutamatergique. Même si le rt-PA induit une meilleure récupération neurologique et augmente les taux circulants de BDNF chez les patients victimes d’un AVC, l’absence de corrélation entre ces deux paramètres n’est pas en faveur de l’utilisation du BDNF circulant comme un marqueur prédictif de récupération neurologique, mais pourrait être un reflet de la capacité de l’endothélium à sécréter le BDNF. / Our objective was to test the hypothesis that the beneficial effect of the administration of the recombinant form of tissue plasminogen activator (rt-PA) in ischemic stroke patient not only results from its fibrinolytic activity but also from its ability to increase brain-derived neurotrophic factor (BDNF) in the brain. To this end, we conducted an initial study to evaluate the effect of rt-PA on brain BDNF levels in healthy animals. In a second study, we investigated the effect of rt-PA on serum BDNF levels in ischemic stroke patients and in animals subjected to permanent focal cerebral ischemia. Blood samples were obtained from patient on admission (D0), D1, D7 and D90 after stroke and in rats before and after (1h, 4h and 24h) ischemia. BDNF was measured in the brain by Western blot and in the blood by ELISA. In both studies, the rt-PA (Actilyse®) was administered as a bolus followed by an infusion of one hour. The first study evidences that 1) rt-PA increases the BDNF levels in the hippocampus, 2) treatment with MK801 (a NMDA receptor antagonist) but not with tranexamic acid (a plasmin inhibitor) canceled the effect of rt-PA on BDNF levels. The second study exhibits that 1) neurological recovery was higher in the patients receiving rt-PA, 2) treatment with rt-PA increases serum BDNF at D1 and D7 in patients, but does not change the blood BDNF levels in animals, 3) BDNF levels are not correlated with neurological recovery but are inversely correlated to the patient cardiovascular score. In conclusion, our results suggest that rt-PA may have a protective extra-fibrinolytic effect by increasing in BDNF levels through a potentiation of glutamatergic pathway. Although rt-PA induces a better neurological recovery and increases circulating BDNF levels in stroke patients, the lack of correlation between these two parameters is not in favor of using circulating BDNF as a predictive marker of neurological recovery, but could be a reflect of the endothelium ability to synthesize BDNF.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Neuroinflammation is a neuropathological finding in a number of neurodegenerative diseases. Intraperitoneal injection of lipopolysaccharide (LPS) induces neuroinflammation and memory deficit. Spermine and spermidine are endogenous polyamines that physiologically modulate the N-methyl-D-aspartate (NMDA) receptor in mammals by binding to the polyamine-binding site at the NMDA receptor. Since polyamines improve memory in cognitive tasks, we tested whether the post-training administration of spermine reverses the deficits of memory induced by LPS in the object recognition task in mice. While spermine (1 mg/kg, i.p.) increased, ifenprodil (10 mg/kg, i.p.), a noncompetitive GluN2B-containing NMDA receptor antagonist, decreased the discrimination score on novel object recognition task. Spermine, at dose that did not alter memory (0.3 mg/kg, i.p.), reversed the cognitive impairment induced by LPS (250 μg/kg, i.p.). Ifenprodil (0.3 mg/kg, i.p.) reversed the protective effect of spermine against LPS-induced memory deficits in the novel object recognition task. However, spermine failed to reverse the LPS-induced increased of cortical and hippocampal cytokines levels. The results indicate that spermine protects from LPS-induced memory deficits in mice by mechanisms other than decreasing LPS-induced cytokine production. / A inflamação periférica desencadeia a produção central de citocinas inflamatórias, gerando um quadro de neuroinflamação. Essa condição altera as transmissões no receptor N-Metil-D-Aspartato (NMDA) o que prejudica a memória e a plasticidade sináptica. A injeção de Lipopolissacarídeo (LPS) induz a neuroinflamação e prejudica a memória. A espermina e a espermidina são poliaminas endógenas que modulam fisiologicamente o receptor NMDA em mamíferos. Uma vez que as poliaminas melhoram a memória em tarefas cognitivas, investigamos se a administração pós-treino de espermina reverte o prejuízo de memória induzido por LPS sistêmico na tarefa de reconhecimento de objetos em camundongos. Enquanto a espermina (1 mg/kg, ip) aumentou, o ifenprodil (10 mg/kg, ip), antagonista não competitivo do receptor NMDA contendo GluN2B, diminuiu a discriminação na tarefa de reconhecimento de objetos. A espermina, em doses que não alteram a memória (0,3 mg/kg, ip), reverteu o dano cognitivo induzido por LPS (250 μg/kg, ip). O ifenprodil (0,3 mg/kg, ip) impediu o efeito protetor da espermina contra o prejuízo de memória induzido por LPS na tarefa de reconhecimento de objetos. No entanto, a espermina não reverteu o aumento dos níveis de citocinas pró-inflamatórias induzido por LPS no hipocampo e córtex cerebral. Os resultados do presente estudo indicam que a espermina protege a piora da memória induzida por LPS em camundongos. O mecanismo desta proteção envolve o sítio de ligação das poliaminas no receptor NMDA, e não envolve mecanismos anti-inflamatórios.

Conselho Nacional de Desenvolvimento Científico e Tecnológico / The morphine addiction is a chronic disease that involves biological, cognitive and behavioral changes developed after repeated and compulsive drug use. Even after long periods of abstinence relapses occur to users, especially when faced with situations that resemble the use thereof. The protocol of conditioned place preference (CPP) has been one of the most widely used experimental models to measure the positive reinforcing effects (conditioned place preference) and negative (conditioned place aversion) of several drugs, including morphine. Studies show that antagonists of the N-methyl-D-aspartate (NMDA) block morphine-induced CPP, suggesting that this receptor is involved in the effects of morphine. Since polyamines act at the NMDA receptor, spermidine (SPD) positive allosteric modulating shape and arcaine acting as an antagonist of the polyamine site on this receiver, the purpose of this study the effect of polyamines on the preference induced conditioned place was to evaluate morphine. Adult male Swiss mice were pre-conditioned once a day for 15 minutes for two consecutive device in the CPP, the next day days were subjected twice daily for conditioning sessions with different drugs and protocols for four consecutive days. Twenty-four hours after the last conditioning session the animals were subjected to the test. The CPP score was calculated for the time spent in the compartment paired with the drug on test day, minus the time spent in the same compartment on the second day of the preconditioning. The results of this study showed that morphine (2.5-10 mg/kg, ip) induced CPP, but not aversion induced conditioned place aversion, the SPD (3-30 mg/kg, ip) and arcaine (0.3-3 mg/kg, ip) did not preferably nor induced conditioned place aversion. However, arcaine (3 mg/kg) administered 15 min before morphine (5 mg/kg) attenuated the pre-training acquisition of morphine-induced PCL. The arcaine (3 mg/kg) administered immediately after conditioning with morphine (5 mg/kg) blocked morphine induced PCL. Also, arcaine (3 mg/kg) administered 30 min pretest blocked morphine induced expression CPP. Furthermore, the effect of arcaine on attenuate the effect of morphine was prevented by the administration of SPD before conditioning, but was not reversed by postconditioning pre-test administration and SPD. These data indicate that arcaine blocks the rewarding effect of morphine and arcaine suggests that it could be a therapeutic target in the development of drugs to treat addiction to morphine. / A adicção a morfina consiste em uma doença crônica que envolve alterações biológicas, cognitivas e comportamentais desenvolvida após o uso repetido e compulsivo da droga. Mesmo após longos períodos de abstinência ocorrem recaídas aos usuários, principalmente quando se deparam com situações que lembram o uso da mesma. O protocolo de preferência condicionada por lugar (PCL) tem sido um dos modelos experimentais mais utilizados para mensurar os efeitos reforçadores positivos (preferência condicionada por lugar) e os negativos (aversão condicionada por lugar) de diversas drogas, incluindo a morfina. Estudos mostram que antagonistas do receptor N-Metil-D-Aspartato (NMDA) bloqueiam a PCL induzida por morfina, sugerindo que este receptor está envolvido nos efeitos da morfina. Uma vez que as poliaminas atuam no receptor NMDA, a espermidina (SPD) modulando de forma alostérica positiva e a arcaína agindo como antagonista do sítio das poliaminas neste receptor, o objetivo deste estudo foi avaliar o efeito das poliaminas sobre a preferência condicionada por lugar induzida por morfina. Camundongos Swiss machos foram pré-condicionados uma vez por dia, durante 15 minutos por dois dias consecutivos no aparelho de PCL, no dia seguinte, foram submetidos, duas vezes por dia às sessões de condicionamento, com diferentes drogas e protocolos durante quatro dias consecutivos. Vinte e quatro horas após a última sessão de condicionamento os animais foram submetidos ao teste. O escore de PCL foi calculado pelo tempo gasto no compartimento pareado com a droga no dia do teste, menos o tempo gasto no mesmo compartimento no segundo dia do pré-condicionamento. Os resultados deste estudo mostraram que a morfina (2,5-10 mg/kg, i.p.) induziu PCL, mas não aversão condicionada por lugar, a SPD (3-30 mg/kg, i.p.) e arcaína (0,3-3 mg/kg, i.p.) não induziram preferência e nem aversão condicionada por lugar. No entanto, a arcaína (3 mg/kg) administrada 15 minutos antes da morfina (5 mg/kg) no pré-treino atenuou a aquisição da PCL induzida por morfina. A arcaína (3 mg/kg) administrada imediatamente após o condicionamento com morfina (5 mg/kg) bloqueou PCL induzida por morfina. Ainda, arcaína (3 mg/kg) administrada 30 min pré-teste bloqueou a expressão PCL induzida por morfina. Além disso, o efeito da arcaína em atenuar o efeito da morfina foi prevenido pela administração de SPD antes do condicionamento, mas não foi revertido pela administração pós-condicionamento e pré-teste de SPD. Estes dados indicam que arcaína bloqueia o efeito de recompensa da morfina e sugere que a arcaína poderia ser um alvo terapêutico no desenvolvimento de drogas para tratar a adicção por morfina.

Spermine (SPM) is an aliphatic amine which contains four nucleophilic centers and is found in all eukaryotic cells, including nervous cells. It belongs to the group of polyamines, which are molecules associated with both neuroprotection and neurotoxicity. The aim of this study was to investigate the effects of spermine on some parameters of toxicity induced by striatal administration of quinolinic acid (QA), an experimental model of Huntington s disease in adult and male Wistar rats. The intrastriatal administration of QA (180 nmol/site) induced contralateral rotations and increase the number of contralateral body swings. The previous striatal administration of SPM caused mixed effects: at the dose of 0.1 nmol/site increased the number of contralateral rotations; but at 10 nmol/site it reduced both the number of rotations and the contralateral body swings induced by QA. The mechanism by which SPM decreases these motor alterations is probably through its interaction with the NMDA receptor, since the co-administration with arcaine (antagonist of polyamine binding sites on this receptor) reversed its protective effect. The increase of protein carbonyl content induced by QA (180 nmol/site) in striatum of rats was prevented by the administration of 10 nmol/site of SPM. Besides, the bilateral striatal injection of QA (180 nmol/site) impaired the performance in the recognition memory task. The post-training striatal administration of SPM (0.1 and 1 nmol/site) reversed the QA-induced cognitive deficit. It was also evaluated whether spermine prevented QA-induced neuromorphological alterations. QA caused striatal neuronal degeneration and reactive astrogliosis. SPM, at the dose that improved the cognitive performance (0.1 nmol/site), had no effect on striatal neuronal degeneration but reversed the intense astrocytic reaction induced by QA. These results suggest that SPM has neuroprotective properties, presenting a dose dependent pattern of polyamine, in this experimental model of Huntington disease. / A espermina (SPM) é uma amina alifática, contendo quatro centros nucleofílicos e é encontrada em todas as células eucarióticas, incluindo células nervosas. Ela pertence ao grupo das poliaminas, moléculas responsáveis tanto por efeitos neuroprotetores quanto neurotóxicos. O objetivo do presente trabalho foi investigar os efeitos da SPM sobre alguns parâmetros de toxicidade induzidos pela administração estriatal de ácido quinolínico (AQ), um modelo experimental da doença de Huntington em ratos Wistar machos adultos. A administração intraestriatal unilateral de AQ (180 nmol/sítio) induziu o aparecimento de rotações contralaterais e aumento do percentual de balanços corporais contralaterais. A prévia administração estriatal de SPM mostrou efeitos diversos: na dose de 0,1 nmol/sítio aumentou o número de rotações; porém na dose de 10 nmol/sítio ela diminuiu tanto o número de rotações quanto o percentual de balanços corporais contralaterais induzidos pelo AQ. O mecanismo pelo qual a SPM diminui estas alterações motoras é, provavelmente, devido à sua interação com o receptor NMDA, uma vez que sua co-administração com a arcaína (antagonista do sítio das poliaminas neste receptor) reverteu o efeito protetor da mesma. A administração de 10 nmol/sítio de SPM preveniu o aumento do conteúdo de proteína carbonil induzida pela injeção de AQ (180 nmol/sítio) no estriado de ratos. Além disso, foi observado prejuízo cognitivo na tarefa de reconhecimento de objetos após a injeção estriatal bilateral de AQ (180 nmol/sítio). A administração estriatal póstreino de SPM (0,1 e 1 nmol/sítio) reverteu este déficit cognitivo induzido pelo AQ. Para avaliação das alterações neuromorfológicas neste modelo foram observadas degeneração neuronal e reação astrocitária. O AQ aumentou significativamente a degeneração de neurônios estriatais e a astrogliose reativa. A SPM, na menor dose que melhorou o desempenho cognitivo (0,1 nmol/sítio), não teve efeito sobre a degeneração neuronal estriatal; no entanto, ela foi capaz de reverter a intensa reação astrocitária induzida pela injeção de AQ. Estes resultados sugerem que a SPM tem propriedades neuroprotetoras, que apresentam um padrão dependente da dose da poliamina, neste modelo experimental da doença de Huntington.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Lesões sistêmicas peri e pré-natais alteram o desenvolvimento do SNC, levando a problemas cognitivos e motores em crianças que podem perdurar por toda a vida. Um tipo particular de lesão é a hipóxia-isquemia (HI), caracterizada pela interrupção momentânea ou permanente do fluxo sanguíneo. Um dos mecanismos propostos para as lesões decorrentes da HI é a excitotoxicidade glutamatérgica. O uso de inibidores da neurotransmissão glutamatérgica tem sido estudados em diversos modelos de HI. Neste trabalho, avaliamos os efeitos morfofuncionais da administração de um antagonista não-competitivo do receptor de glutamato NMDA sobre o desenvolvimento do cerebelo. Ratas no 18 dia de gestação foram anestesiadas, os cornos uterinos expostos e as 4 artérias uterinas obstruídas por 45 minutos (Grupo H). Animais controle tiveram os úteros expostos, sem a obstrução (Grupo S). Após a cirurgia a gestação prosseguiu. Somente animais nascidos a termo foram utilizados. Um dia após o nascimento, metade de cada ninhada foi designada para receber MK801, 0,3mg/kg/dia, (grupos SM e HM) e a outra metade recebeu solução salina (grupos SS e HS), por 5 dias. Após anestesia e perfusão-fixação com paraformaldeído 4% aos 9, 23, 30 e 60 dias pós-natais, cortes parassagitais do cerebelo foram obtidos em criótomo e submetidos à imunohistoquímica para calbindina, GFAP, GLAST, PDGFRα e MBP. A partir de 45 dias de vida, os animais foram testados em vários de testes comportamentais: labirinto em cruz elevado (LCE), campo vazado (CV), ROTAROD, teste de caminhada sobre barras (ladder test) e teste do comprimento da passada (stride length). Aos 9 dias, a espessura da árvore dendrítica era menor nos animais SM, HS/HM, demonstrando efeitos deletérios tanto do MK801 quanto da HI. Menor número de células PDGFRα+ foi observado nos animais HS/HM, sem efeitos da administração de MK801. Aos 23 dias, maior número de células PDGFRα+ foi observado nos animais HM comparado aos outros 3 grupos, indicando efeito neuroprotetor do MK801. Nessa idade, menor número de fibras mielinizadas (MBP+) foi observada nos animais HS, e a administração de MK801 parece reverter estes efeitos. Aos 9 dias a distribuição de GLAST estava alterada nos animais HS, com os efeitos da HI parcialmente revertidos pelo MK801. Não foram observados efeitos da HI ou do MK801 sobre comportamentos relacionados a ansiedade pelo LCE, assim como na latência de queda no ROTAROD. HI piora a performance motora no ladder test. No teste do CV, não observamos efeitos da HI sobre a busca por novidade assim como sobre a atividade locomotora espontânea. No entanto, MK801 diminui comportamentos de autolimpeza e a atividade locomotora espontânea. Menor variação das passadas foi observada em decorrência da administração de MK801 no stride length, com nenhum efeito da HI. Nossos resultados demonstram que a inibição do receptor NMDA tem um efeito neuroprotetor sobre os progenitores de oligodendrócitos e mielinização, provavelmente pela manutenção da capacidade proliferativa por um período maior. A atividade do receptor NMDA exerce importante papel na diferenciação das células de Purkinje, assim como na distribuição do transportador GLAST, corroborando a importância deste receptor na gênese das lesões causadas pela HI. / Peri and prenatal systemic lesions alter CNS development leading to motor and cognitive problems in children that might persist throughout life. A particular kind of injury, the hypoxic ischemic (HI), is characterized by a permanent or temporary blockage of blood flow. One of the proposed mechanisms downstream from a HI event is called glutamatergic excitotoxicity. The administration of glutamate inhibitors has been studied in HI models for several years. In this work, we evaluated the effects of administration of a non-competitive antagonist of glutamate receptor, NMDA, on cerebellar development and behavioral tests of HI animals. Pregnant rats in the 18th gestational day were anesthetized, the uterine horns were exposed and the four uterine arteries were clamped for 45 minutes (group H). Sham controls had the uterine horns exposed, but no arteries were clamped (group S). Gestation proceeded after surgery. Only full term animals were used. One day after birth half the animals was assigned to receive either SALINE (groups SS and HS) or MK801 (groups SM and HM). Animals were anesthetized and perfused with 4% paraformaldehyde at 9, 23, 30 and 60 days of age. Parasagittal cerebellar sections were submitted to Calbindin, GFAP, GLAST, PDGFRα and MBP immunohistochemistry. Beginning at P45 animals were subjected to a battery of behavioral tests: elevated plus maze (EPM), hole board (HB), ROTAROD, ladder test and stride length. At P9 the dendritic tree of Purkinje cells were thinner in SM, HS/HM animals, indicating that both HI and MK801 are deleterious regarding this Purkinje cell differentiation. A lower number of PDGFRα+ cells was observed in HS/HM animals, with no effects of MK801 administration. At P23 a greater number of PDGFRα+ cells was found in HM animals when compared to the other 3 groups, demonstrating a neuroprotector effect of MK801. A lower number of myelinated fibers (MBP+) was observed in HS animals at P9, and MK801 administration reverse this effect. At P9, GLAST distribution was altered in HS animals, and MK801 partially reverse this altered distribution. No effects of HI and MK801 were observed in the EPM and ROTAROD tests. HI decreased motor performance of hind limbs in the ladder test, though no effect of MK801 was noted. In the HB test, we do not observe HI effects regarding the novelty seeking behavior and locomotor activity, otherwise the administration of MK801 decreased the number of grooming and locomotor activity. In the stride length test, we do not observed effects of HI although MK801 augmented the length variation of the fore limbs. Our results show that inhibition of NMDA receptors exerts a neuroprotector effect on oligodendrocyte progenitor cells and myelination, probably by temporarily inhibiting differentiation of those, providing more time to proliferate. NMDA activity exerts a crucial role in Purkinje cell differentiation as well as in GLAST distribution. Taken together our results lead us to conclude that NMDA receptor activity has an important role in the genesis of lesions caused by HI events.